Cargando…

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance

Detalles Bibliográficos
Autores principales:	Raschi, Emanuel, Fusaroli, Michele, Diemberger, Igor, Poluzzi, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447592/ https://www.ncbi.nlm.nih.gov/pubmed/32845443 http://dx.doi.org/10.1007/s40264-020-00990-9

Ejemplares similares

Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
por: Giugliano, Robert P., et al.
Publicado: (2021)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
por: Mei, Riccardo, et al.
Publicado: (2018)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
por: Gatti, Milo, et al.
Publicado: (2021)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
por: Fusaroli, Michele, et al.
Publicado: (2023)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Dalmazi, Guido D, et al.
Publicado: (2022)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
por: Lunghi, Carlotta, et al.
Publicado: (2022)

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2023)

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
por: Noguchi, Yoshihiro, et al.
Publicado: (2023)

Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
por: Gatti, Milo, et al.
Publicado: (2020)

Factors associated with prescription of oral anticoagulants in the era of direct oral anticoagulants
por: Kataoka, Naoya, et al.
Publicado: (2023)

Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
por: Raschi, Emanuel, et al.
Publicado: (2016)

Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap
por: Conti, Nicolina, et al.
Publicado: (2021)

Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
por: Bellesini, Marta, et al.
Publicado: (2020)

Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network
por: Lavalle, Carlo, et al.
Publicado: (2022)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome
por: Giarretta, Igor, et al.
Publicado: (2022)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services
por: Sylvester, Katelyn W., et al.
Publicado: (2018)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants
por: Garkina, Svetlana V, et al.
Publicado: (2016)

Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
por: Poluzzi, Elisabetta, et al.
Publicado: (2014)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

The efficacy and safety of out-hospital anticoagulation therapy with direct oral anticoagulant for COVID-19
por: Geng, Yu, et al.
Publicado: (2023)

Direct oral anticoagulant use in left ventricular thrombus
por: Ali, Zafar, et al.
Publicado: (2020)

More Smart Use of Direct Oral Anticoagulants in Geriatric Patients [Letter]
por: Zhu, Ling-Ling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a116douain2l934ivh1gh52mkf